The authors showed that elevated ABLIM1 expression in CRC patients correlated with shorter disease-free survival, suggesting its potential as a prognostic biomarker for predicting disease relapse in CRC patients. The gene discussed is ABLIM1; the disease is colorectal carcinoma.